Hepatocellular carcinoma (HCC) is one of the most prevalent human cancers in the world,
but its prognosis is extremely poor. HCC is considered a hypervascular tumor. Thalidomide …

BACKGROUND The hypervascular nature of hepatocellular carcinoma (HCC) is well
characterized. Recent data have suggested that thalidomide possesses antiangiogenic and …

Objective: The systemic treatment of advanced hepatocellular carcinoma (HCC) has
produced disappointing results thus far. HCC is a hypervascular tumor with over-expression …

Objectives: Thalidomide has been shown to have antitumor activity in some patients with
advanced hepatocellular carcinoma (HCC). We initiated a phase II study to determine the …

BACKGROUND The treatment of patients with hepatocellular carcinoma (HCC) presents a
major challenge, because associated cirrhosis limits the choice of chemotherapeutic agents …

15076 Background: thalidomide has been reported to have anti-angiogenic properties and
therefore has been studied in several hypervascularized cancers. We evaluated the effect of …

Background The high vascularity of hepatocellular carcinoma (HCC) seems to be a potential
therapeutic target. We evaluated the efficacy, toxicity, and histologic response to thalidomide …

Objective: To analyze the efficacy of oral thalidomide in the treatment of advanced
hepatocellular carcinoma (HCC). Methods: Sixty-eight patients with unresectable and …

AIM: To evaluate the efficacy of thalidomide in combination with other therapies to treat
patients with advanced hepatocellular carcinoma (HCC). METHODS: We performed a …

Hepatocellular carcinoma (HCC) is a hypervascular tumour, which overexpresses vascular
endothelial growth factor. Thalidomide is an antiangiogenic agent with activity in refractory …